Literature DB >> 18702389

Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.

Linda Jose1, Chacko Binila, S J Chandy, J E Mathews, K P Mathews.   

Abstract

This case report describes a rare interaction between therapeutic doses of phenytoin and acenocoumarol resulting in both acute phenytoin toxicity and increased international normalized ratio (INR). Interactions between these drugs are due to the pharmacokinetics and the common metabolising pathway by hepatic cytochrome P450 isoenzyme-CYP2C9. Our patient was detected to be homozygous for CYP2C9*3 by PCR-RFLP analysis resulting in markedly decreased metabolism of both the drugs. Given that these two drugs are often given concomitantly in the medical out patient department, and that CYP2C9 polymorphisms are not uncommon, clinicians should be aware of this interaction and suspect this in patients with toxicity to these drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702389

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  4 in total

1.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

Review 2.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2011-02-11

3.  The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery.

Authors:  Seyhan Yağar; Soner Yavaş; Bensu Karahalil
Journal:  Mol Biol Rep       Date:  2010-11-23       Impact factor: 2.316

Review 4.  From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.

Authors:  Bob Wilffert; Jesse Swen; Hans Mulder; Daan Touw; Anke-Hilse Maitland-Van der Zee; Vera Deneer
Journal:  Int J Clin Pharm       Date:  2010-11-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.